- Home
- FMN vs IPHA Comparison
FMN vs IPHA Comparison
Compare FMN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMN
- IPHA
- Stock Information
- Founded
- FMN 2002
- IPHA 1999
- Country
- FMN United States
- IPHA France
- Employees
- FMN N/A
- IPHA N/A
- Industry
- FMN Investment Managers
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- FMN Finance
- IPHA Health Care
- Exchange
- FMN Nasdaq
- IPHA Nasdaq
- Market Cap
- FMN 127.6M
- IPHA 148.3M
- IPO Year
- FMN N/A
- IPHA 2019
- Fundamental
- Price
- FMN $11.09
- IPHA $1.69
- Analyst Decision
- FMN
- IPHA Strong Buy
- Analyst Count
- FMN 0
- IPHA 1
- Target Price
- FMN N/A
- IPHA $11.50
- AVG Volume (30 Days)
- FMN 22.8K
- IPHA 49.9K
- Earning Date
- FMN 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- FMN 3.86%
- IPHA N/A
- EPS Growth
- FMN N/A
- IPHA N/A
- EPS
- FMN N/A
- IPHA N/A
- Revenue
- FMN N/A
- IPHA $36,202,722.00
- Revenue This Year
- FMN N/A
- IPHA N/A
- Revenue Next Year
- FMN N/A
- IPHA $101.65
- P/E Ratio
- FMN N/A
- IPHA N/A
- Revenue Growth
- FMN N/A
- IPHA N/A
- 52 Week Low
- FMN $9.09
- IPHA $1.29
- 52 Week High
- FMN $11.31
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- FMN 53.89
- IPHA 42.95
- Support Level
- FMN $10.78
- IPHA $1.60
- Resistance Level
- FMN $10.93
- IPHA $1.87
- Average True Range (ATR)
- FMN 0.08
- IPHA 0.13
- MACD
- FMN 0.04
- IPHA -0.04
- Stochastic Oscillator
- FMN 88.57
- IPHA 16.67
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers.. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.